GSK completed the spin-off of its consumer healthcare division into a separate public company, Haleon. GSK distributed to shareholders 80% of its stake in Haleon, which was 68%. The new company received a portfolio of drugs such as Sensodyne, Voltaren, Panadol and Centrum. Haleon stock will begin trading today on the LSE under the ticker symbol HLN. In addition, GSK will do a 4-to-5 stock consolidation today.